

Lesley McGuffog

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7773110/publications.pdf>

Version: 2024-02-01

44
papers

5,556
citations

218592

26
h-index

223716

46
g-index

48
all docs

48
docs citations

48
times ranked

8553
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	3.8	1,898
2	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
4	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
5	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
6	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	242
7	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
8	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
9	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
10	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
11	Combined genetic and splicing analysis of <i>BRCA1</i> c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	1.4	106
12	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
13	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
14	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	0.8	90
15	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
16	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
18	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78

#	ARTICLE	IF	CITATIONS
19	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
20	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
21	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
22	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
23	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
24	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
25	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. <i>Human Mutation</i> , 2019, 40, e1-e23.	1.1	34
26	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
27	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
28	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
29	The <i>FANCM</i> :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
30	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
31	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for <i>BRCA1</i> pathogenic variant carriers. <i>European Journal of Human Genetics</i> , 2017, 25, 432-438.	1.4	26
32	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. <i>Human Mutation</i> , 2019, 40, 1781-1796.	1.1	26
33	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
34	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
35	The <i>BRCA2</i> c.68-7T>A variant is not pathogenic: A model for clinical calibration of spliceogenicity. <i>Human Mutation</i> , 2018, 39, 729-741.	1.1	19
36	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19

#	ARTICLE	IF	CITATIONS
37	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
38	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
39	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
40	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
41	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
42	Lymphocyte Telomere Length Is Long in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Regardless of Cancer-Affected Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1018-1024.	1.1	13
43	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
44	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5